Skip to main content
Equibles
LSTA logo

LSTA · Lisata Therapeutics, Inc.

Track LSTA — free

Use LSTA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LSTA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.15 +0.07 (+6.48%) At close · Aug 18
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on its current business plan and current capital resources, combined with the need to raise additional funding and the uncertainty regarding the availability of such additional funding, management has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a period of twelve months after the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$9.73M
Shares
9.01M

Lisata Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Lisata Therapeutics, Inc. (LSTA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$37.38M '22 Q3 22-11-10 · $ −$6.19M '23 Q1 23-05-09 · $ −$4.03M '23 Q2 23-08-14 · $ −$5.26M '23 Q3 23-11-02 · $ −$5.37M '23 Q4 24-02-29 · $ −$5.40M '24 Q1 24-06-27 · $ −$5.04M '24 Q2 24-08-12 · $ −$4.93M '24 Q3 24-11-12 · $1.00M −$4.61M '24 Q4 25-02-27 · $ −$4.72M '25 Q1 25-05-08 · $70,000 −$4.66M '25 Q2 25-08-07 LATEST · $ −$4.25M '25 Q3 25-11-06
Earnings call
FY25 · Q3
2025-11-06
Lisata Therapeutics, Inc. Q3 FY2025 Earnings Call
Positive tone certepatide clinical development Phase 3 planning and funding business development and licensing
Revenue
$
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Lisata Therapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone Certepetide clinical development Intellectual property / patents Regulatory interactions and designations
Revenue
$70,000
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Lisata Therapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone Certepetide clinical pipeline China partnership with Qilu Tethered delivery / ADC collaboration
Revenue
$
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Lisata Therapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$1.00M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Lisata Therapeutics, Inc. Q3 FY2024 Earnings Call
Positive tone Certepetide clinical development ASCEND trial in mPDAC Partnered / investigator-sponsored collaborations
Revenue
$
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Lisata Therapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone Certepetide clinical pipeline advancement Clinical trial enrollment and progress Geographic site and operational updates
Revenue
$
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-06-27
Lisata Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone Lead candidate certepetide (LSTA1) development Phase 2a BOLSTER trial Manufacturing cost and pharmacoeconomics
Revenue
$
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Lisata Therapeutics, Inc. Q4 FY2023 Earnings Call
Positive tone LSTA1 lead candidate Qilu partnership and milestones Clinical pipeline progress
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Lisata Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Lisata Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Lisata Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.77
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Lisata Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Lisata Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-7.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Lisata Therapeutics, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-1.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Lisata Therapeutics, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Lisata Therapeutics, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Lisata Therapeutics, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-1.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Lisata Therapeutics, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-1.50
▼ 120% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Lisata Therapeutics, Inc. Q1 FY2021 Earnings Call
Diluted EPS
$-2.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Lisata Therapeutics, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Lisata Therapeutics, Inc. Q3 FY2020 Earnings Call
Diluted EPS
$-4.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Lisata Therapeutics, Inc. Q2 FY2020 Earnings Call
Diluted EPS
$7.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Lisata Therapeutics, Inc. Q1 FY2020 Earnings Call
Diluted EPS
$-5.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Lisata Therapeutics, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 320017 CUSIP 128058302 13F (30d) 32 filings 32 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)